TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04416035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRS003
Description: TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: China-approved Bevacizumab
Description: China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
Study: NCT02956213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA portable air filter
Description: A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Control/Active Comparator
Description: A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
Study: NCT00651482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT06566391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
Study: NCT00651482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02820194

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
Study: NCT00607945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant
Description: Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant
Description: Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant
Description: Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: conjugated linoleic acid (CLA)
Description: 3.2 g/day, capsule, week 0 to week 32
Study: NCT02263677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
Study: NCT04222218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
Study: NCT00607945

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: conjugated linoleic acid (CLA)
Description: 6.4 g/day, capsule, week 0 to week 32
Study: NCT01159301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02321982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-day preoperative consultation
Description: Preoperative consultation occurs on the same day as Mohs surgery
Study: NCT04441450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]ICP-022
Description: 150mg suspension containing 100μCi of \[14C\]ICP-022
Study: NCT03064126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RANGER™ Paclitaxel Coated Balloon
Description: A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The RANGER™ Balloon is coated with the drug Paclitaxel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Balloon Angioplasty
Description: A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries.
Study: NCT03229564

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHSG-KF
Description: Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHSG-KF
Description: Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin graft to the control area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin graft to the control area
Study: NCT01764776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225
Study: NCT04402944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: Pulmozyme 2.5 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 2.5 mL BID
Study: NCT02237885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroSky MindWave Mobile
Study: NCT02916056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon 5mg
Study: NCT03978806

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: peer navigator
Description: The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
Study: NCT03643822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
Study: NCT03978806

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control Arm (standard of care)
Description: Control patients will have met the same inclusion and exclusion criteria as intervention patients.
Study: NCT04035993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycaemic state while driving with a driving simulator
Description: Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes.
Study: NCT04027907

Intervention type: OTHER
Intervention: Flowcytometry
Description: detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).

Intervention type: OTHER
Intervention: Flowcytometry
Description: detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
Study: NCT03643822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Control/Placebo intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Control/Placebo intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Control/Placebo intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Control/Placebo intervention
Study: NCT03916627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum Doublet
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum Doublet
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum Doublet
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Administered IV
Study: NCT02512497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI \>4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
Study: NCT02260570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: COMT Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A pill that contains no active ingredient
Study: NCT04273763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablets
Description: Bromhexine Hydrochloride Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol Hydrochloride Granules
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbidol Hydrochloride Granules
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon α2b Spray
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Interferon α2b Spray
Description: Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
Study: NCT02684370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: Ustekinumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ustekinumab
Description: Placebo for ustekinumab administered by subcutaneous (SC) injection
Study: NCT01703949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01112384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: Given orally 3 times per week
Study: NCT01787084

Intervention type: DEVICE
Intervention: Edwards SAPIEN Transcatheter Heart Valve
Description: Non-femoral transcatheter delivery of heart valve
Study: NCT02399085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: 12 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg
Study: NCT04146480

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F18-NaF PET/CT
Description: The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions.
Study: NCT01859715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone
Description: Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
Study: NCT04242056

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-PM-PBB3
Description: 18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets.
Study: NCT04487327

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique.
Study: NCT01825369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV L-carnitine
Description: See arm description